Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ISIS 678354-CS9 Phase 3 Study of Olezarsen in Hypertriglyceridemia and ASCVD or Severe Hypertriglyceridemia
2022-503022-13-00Phase 3Completed
- Sponsor
- Ionis Pharmaceuticals
- Start
- May 2023
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 15
01
Overview
Phase 3, randomised, double-blind trial in hypertriglyceridemia, atherosclerotic disease and cardiac morbidity comparing Olezarsen with Placebo (2 arms). Primary endpoint: Percent change in fasting triglycerides at Week 25. Started May 2023; status: completed.
02
Drugs
olezarsen
03
Conditions
hypertriglyceridemiaatherosclerotic diseasecardiac morbidity
Beyond the preview
Go deeper on 2022-503022-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-503022-13-00.